ECSP13012431A - Combinación del compuesto glyt1 con antipsicóticos - Google Patents

Combinación del compuesto glyt1 con antipsicóticos

Info

Publication number
ECSP13012431A
ECSP13012431A ECSP13012431A ECSP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A
Authority
EC
Ecuador
Prior art keywords
glyt1
combination
antipsychotics
compound
schizophrenia
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Luc Moreau
Joseph G Wettstein
Daniela Alberati
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13012431A publication Critical patent/ECSP13012431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de un inhibidor del transportador de glicina (GlyT1) y un fármaco antipsicótico atípico que puede utilizarse para el tratamiento de los síntomas positivos y negativos de la esquizofrenia.
ECSP13012431 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos ECSP13012431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09

Publications (1)

Publication Number Publication Date
ECSP13012431A true ECSP13012431A (es) 2013-03-28

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012431 ECSP13012431A (es) 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos

Country Status (28)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP6255082B2 (ja) 2013-03-13 2017-12-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびその使用方法
WO2015082367A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
IL248567B (en) * 2014-04-30 2022-08-01 Univ Nat Taiwan Use of compounds known as d-amino acid oxidase inhibitors
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20170065637A (ko) * 2014-10-07 2017-06-13 세이지 테라퓨틱스, 인크. 신경활성 화합물 및 그의 사용 방법
KR20180026742A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2018519351A (ja) 2015-07-06 2018-07-19 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
BR112018070123A2 (pt) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós e métodos de uso dos mesmos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN117064892A (zh) * 2017-11-14 2023-11-17 爱思开生物制药株式会社 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物
JP2023509792A (ja) 2020-01-09 2023-03-09 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297458T3 (es) * 2003-08-11 2008-05-01 F. Hoffmann-La Roche Ag Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti.
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
ES2520015T3 (es) * 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
AU2011288536A1 (en) 2013-01-31
CR20130027A (es) 2013-03-04
EP2603219A1 (en) 2013-06-19
KR101455947B1 (ko) 2014-10-28
CY1115886T1 (el) 2017-01-25
MA34457B1 (fr) 2013-08-01
DK2603219T3 (da) 2014-10-13
EP2603219B1 (en) 2014-09-17
TW201211019A (en) 2012-03-16
SI2603219T1 (sl) 2014-12-31
CA2803656A1 (en) 2012-02-16
MX2013001166A (es) 2013-03-22
PL2603219T3 (pl) 2015-03-31
CL2013000378A1 (es) 2013-05-03
PT2603219E (pt) 2014-11-25
CN103068388A (zh) 2013-04-24
NZ604891A (en) 2015-01-30
US20120035156A1 (en) 2012-02-09
AU2011288536B2 (en) 2014-10-09
EA201291477A1 (ru) 2013-06-28
WO2012019970A1 (en) 2012-02-16
KR20130045379A (ko) 2013-05-03
HRP20141199T1 (hr) 2015-02-13
BR112013003068A2 (pt) 2016-06-28
ES2521596T3 (es) 2014-11-13
ZA201300434B (en) 2013-09-25
SG187108A1 (en) 2013-02-28
AR084401A1 (es) 2013-05-15
JP2013533297A (ja) 2013-08-22
PE20131100A1 (es) 2013-09-23

Similar Documents

Publication Publication Date Title
ECSP13012431A (es) Combinación del compuesto glyt1 con antipsicóticos
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
CR20130616A (es) Amidas-2-piridina útiles como agonistas cb2
CR20150447A (es) Nuevos derivados de pirazol
GT201200230A (es) Inhibidores del virus de la hepatitis c
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
GT201300215A (es) Inhibidores de glucosilceramida sintasa
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
ECSP13012414A (es) Combinaciones que comprenden antipsicóticos atípicos y agonistas taar1
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
CR20150275A (es) Composición de difenidol de liberación prolongada
NI201500171A (es) Formulaciã“n oral para el tratamiento de enfermedades cardiovasculares
SV2015004997A (es) Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento
CL2015000610A1 (es) Derivados de isoxazolidina